15 julho 2014

Inscrições abertas para o 5° Congresso Brasileiro sobre o Uso Racional de Medicamentos

Farmacêuticos, médicos, odontólogos, enfermeiros, agentes de saúde, gestores e estudantes da área da saúde já podem se inscrever para o 5º Congresso Brasileiro de Uso Racional de Medicamentos. O evento será que será realizado no Anhembi Parque - Palácio das Convenções, em São Paulo de 22 a 25 de setembro. O congresso é organizado pelo Comitê Nacional de Promoção do Uso Racional de Medicamentos, composto por representantes do Ministério da Saúde, Organização Pan-Americana da Saúde (Opas), Agência Nacional de Vigilância Sanitária(Anvisa) entre outras entidades.

A expectativa é que mais de 2.500 congressistas participem desta edição que terá como tema central “O Uso Racional de Medicamentos e a Segurança do Paciente”, escolhido de acordo com as demandas atuais mais discutidas na área e pela criação recente do Programa Nacional de Segurança do Paciente (PNSP), que busca qualificar o cuidado em todos os estabelecimentos de saúde do território nacional.


“O Comitê verificou que os temas dos quatro primeiros congressos sempre foram voltados aos profissionais. Assim, entendeu que nesta edição o congresso deveria extrapolar, tendo a sociedade como parceira, levando a discussão do Uso Racional de Medicamentos para a população”, explica Marco Aurélio Pereira, coordenador do programa Farmácia Popular do Brasil, do Ministério da Saúde e membro do Comitê de Uso Racional de Medicamentos.

Os participantes do V Congresso Brasileiro sobre Uso Racional de Medicamentos poderão assistir a conferências, mesas redondas, painéis, oficinas e cursos, que contarão com a participação de consagrados palestrantes nacionais e internacionais.

A promoção do Uso Racional de Medicamentos faz parte das estratégias da Organização Mundial de Saúde (OMS). No Brasil, o Uso Racional de Medicamentos é prioridade na agenda de saúde.
Para se inscrever, acesse o site www.saude.gov.br/congressourm. As inscrições para o Congresso poderão ser feitas até o dia 15 de setembro, já as inscrições de trabalhos serão realizadas de 13 de junho a 13 de julho de 2014.

Sobre o CNPURM - O Comitê Nacional para a Promoção do Uso Racional de Medicamentos (CNPURM) foi instituído em 2007 e redefinido por meio da Portaria nº 834, de 14 de maio de 2013. Tem por finalidade orientar e propor ações, estratégias e atividades para a promoção do uso racional de medicamentos no âmbito da Política Nacional de Promoção da Saúde, visando ampliar e qualificar o acesso a medicamentos que atendam aos critérios de qualidade, segurança e eficácia.

Congresso Brasileiro sobre o Uso Racional de Medicamentos
Data: 22 a 25 de setembro de 2014
Local: Anhembi Parque - Palácio das Convenções, em São Paulo
Inscrições e programação: www.saude.gov.br/congressourm.

04 julho 2014

CONGRESSOS na área farmacêutica em 2014

CURSO PROTOCOLO DE SEGURANÇA NA PRESCRIÇÃO, USO E ADMINISTRAÇÃO DE MEDICAMENTOS.

Data: 25 e 26 de julho de 2014
Local: Belo Horizonte - MG

***

VI SIMPÓSIO NACIONAL DE CANCEROLOGIA DA AERINCA.

Data: 21 e 22 de agosto de 2014
Local: Rio de Janeiro - RJ

***
  
II FÓRUM BRASILEIRO SOBRE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA.

Data: 14 a 17 de setembro de 2014
Local: Salvador - BA

***

9º SIMPÓSIO INTERNACIONAL DE ESTERILIZAÇÃO E CONTROLE DE INFECÇÃO HOSPITALAR.

Data: 17 a 20 de setembro de 2014
Local: São Paulo - SP

***

V CONGRESSO BRASILEIRO SOBRE O USO RACIONAL DE MEDICAMENTOS.

Data: 22 a 25 de setembro de 2014
Local: São Paulo - SP
Contatos: www.saude.gov.br

***

VIII CONGRESSO FRANCO BRASILEIRO DE ONCOLOGIA.

Data: 09 a 11 de outubro de 2014
Local: Rio de Janeiro - RJ

***

IV CONGRESSO DE FARMÁCIA HOSPITALAR EM ONCOLOGIA DO INCA.

Data: 30, 31 de outubro e 01 de novembro de 2014
Local: Rio de Janeiro - RJ

***

CONGRESSO BRASILEIRO DE HEMATOLOGIA, HEMOTERAPIA E TERAPIA CELULAR.

Data: 06 a 09 de novembro de 2014
Local: Florianópolis - SC
Contatos: www.hemo.org.br

***


II BIENAL INTERNACIONAL DE ONCOLOGIA 2014.

Data: 06 a 08 de novembro de 2014
Local: São Paulo - SP

***
  
XVI CONGRESSO BRASILEIRO DE CONTROLE DE INFECÇÃO HOSPITALAR E EPIDEMIOLOGIA HOSPITALAR.

Data: 19 a 22 de novembro de 2014
Local: Curitiba - PR
Contatos: www.abev.com.br

***

XIV CONGRESSO BRASILEIRO DE ONCOLOGIA PEDIÁTRICA.

Data: 27 a 30 de novembro de 2014
Local: Brasília - DF

15 junho 2014

IMPLEMENTATION OF A CLINICAL PHARMACY SERVICE AND ANALYSIS OF THE PHARMACOTHERAPEUTIC INTERVENTIONS IN THE NEUROLOGY SECTOR OF HCFMRP/USP

JOÃO PAULO VILELA RODRIGUES, LILIAN PEREIRA PRIMO, LORENA ROCHA AYRES, LEONARDO RÉGIS LEIRA PEREIRA, ALEXANDRA CRUZ ABRAMOVICIUS

Centro de Pesquisa em Assistência Farmacêutica e Farmácia Clínica, Universidade de São Paulo, Brasil - Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (HCFMRP/USP), Universidade de São Paulo, Brasil

Introduction: Neurological diseases are common in the population and there is a lack of well defined protocols for the treatment of some of them. The management of drug therapy is also difficult in relation to toxicity, drug interactions and complexity of treatment. Clinical Pharmacy (CP) is a tool that can provide safe and effective therapies to hospitalized patients. The aim of this study is to describe the pharmacotherapeutic interventions (PI) conducted by clinical pharmacists and the degree of acceptance by physicians during the first year of this service implementation in Neurology Sector of Hospital das Clínicas de Ribeirão Preto (HCFMRP-USP).

Methods: We retrospectively revised pharmacists’ interventions records from 109 hospitalized patients between December, 2011 and December, 2012. We included adults of both sexes, regardless of the reason of admission. It was considered only the PI performed together with the medical staff that was documented.

Results: The CP team made 74 PI, of which 64 (86%) were accepted by the physicians. There were sixteen dose changes, twelve discontinuations due to adverse reactions and/or drug interactions, eighteen changes in forms of administration, nine discontinuation unnecessary and/or ineffective treatment, two changes in treatment period, four introduction of a new drug, nine drug or treatment changes and four pharmaceutical formulation changes.

Conclusion: The results show that CP is an important tool for the safety and effectiveness of the treatment of hospitalized patients, which is confirmed by the high degree of adherence from the medical team to the PI performed.

Rev.Bras. Farm. – 94 (4); 2013

28 maio 2014

PHARMACIST IDENTIFICATION OF POTENTIAL SIDE EFFECTS IN PATIENTS WITH MULTIMORBIDITY AND POLYPHARMACY

L Jeffery, MG Kruse; Silkeborg Regional Hospital, Viborg Hospital Pharmacy, Silkeborg, Denmark

Background Denmark’s first outpatient clinic for multimorbidity and polypharmacy opened at Silkeborg Regional Hospital in 2012. The clinic treats patients with at least 2 chronic illnesses, who present with a variety of symptoms. The pharmacist is an integral member of the multidisciplinary team that sees the patient during a single visit. The team includes a nurse, medical consultant, physio- and occupational therapist, and relevant senior doctors from 9 other medical specialities, including psychiatry.

Purpose To document the impact of a pharmacist on identification of potential side effects to regular medicines and on other medicines-related problems (MRP) in patients at a clinic for patients with multimorbidity.

Materials and methods Before the patient sees the consultant, the pharmacist interviews the patient about all aspects of his medicines history (including over the counter medicines and herbal/natural medicines) and updates the electronic prescribing system. A full medicines review is then carried out with extra focus on possible side effects. The pharmacist presents relevant MRP to the doctor before the patient’s consultation. The pharmacist is also present at the following multidisciplinary conference about the patient. MRP found are recorded in a national database (LRP database).

Results The pharmacist saw 58 patients from May 2012 to September 2013 and highlighted 208 MRP. The patients at the clinic have on average 12.3 (3–26) regular medicines. Twenty-nine patients had potential side effects to their regular medicines (from 1–11). Ninety-four (45%) of the pharmacist’s 208 suggestions were implemented at the clinic, where 20 were related to the 70 highlighted possible side effects.

Conclusions With special focus on side effects to regular medicines, the pharmacist highlighted potential side effects in 50% of the patients at the clinic for multimorbidity and polypharmacy. Despite the clinic being an outpatient clinic, the acceptance rate for the pharmacist’s suggestions was surprisingly high.

Eur J Hosp Pharm 2014:21(Suppl 1):A1–224

19 abril 2014

EVALUATION OF OCCUPATIONAL EXPOSURE TO ANTINEOPLASTIC DRUGS IN PHARMACY AND ONCOLOGY DEPARTMENT

E Korczowska, H Jankowiak-Gracz, PJM Sessink, E Grzeskowiak.

Clinical Hospital of Lord’s Transfiguration The University of Medical Sciences, Pharmacy, Poznan, Poland; Exposure Control Sweden AB, Bohus-Björkö, Sweden; Poznan University of Medical Sciences, Department of Clinical Pharmacy and Biopharmacy, Poznan, Poland

Background Several studies have shown evidence of adverse health effects associated with exposure to antineoplastic drugs. Hospital personnel involved in preparation and administration of antineoplastic drugs may be at risk if exposed to these hazardous pharmaceuticals.

Purpose The purpose of the study was to evaluate the potential exposure to antineoplastic drugs in the pharmacy and oncology departments in a Polish hospital under normal working conditions. The exposure was measured by determining cyclophosphamide (CP) in the urine of pharmacists, physicians and nurses.

Materials and Methods Eight hospital workers were included in the study. Urine samples were collected from 2 pharmacists, 2 physicians and 4 nurses. One pharmacist prepared antineoplastic drugs while the other pharmacist assisted. All four nurses in the oncology department were engaged in the administration of the drugs. The two physicians did not handle the drugs but they came in contact with treated patients. Total 24 h urine was collected in fractions and from each fraction the volume was recorded and used to calculate the total amount of CP excreted over the 24 hr period. Samples were collected with Cyto Urine Kits from Exposure Control Sweden AB. Samples were stored frozen until analysis with GC-MSMS.

Results Over the 24 hr periods, 62 urine samples from 8 hospital workers were collected. CP was detected in 31 urine samples (50%) involving all pharmacists, all physicians and 3 nurses. The total amount of CP excreted per worker ranged from 106 to 500 ng/24 hr. The mean amount of CP excreted per worker on group basis was 234 ng/24 hr (physicians: 343 ng/24 hr, pharmacists: 239 ng/24 hr, nurses: 177 ng/24 hr). The highest amount of CP excreted was found for one physician (500 ng/24 hr) and for one nurse (492 ng/24 hr). The amount of CP excreted in urine from the pharmacist who assisted in preparation (358 ng/24 hr) was higher than from the pharmacist who prepared the chemotherapy infusions (120 ng/24 hr). CP was not detected in the urine samples of one nurse indicating no measurable exposure to CP.

Conclusions The results show that almost all hospital workers tested were exposed to CP. In addition, the study demonstrates the highest exposure of personnel not directly involved in the preparation and administration of antineoplastic drugs. Clearly, more research is needed, but this is suffi cient evidence that nurses and physicians involved in the area of cytotoxic administration on the ward can also be exposed to these hazardous drugs.

Reference Eur J Hosp Pharm 2013;20(Suppl 1):A1–A238

30 março 2014


1ª Ed. 2014 Editora Medfarma
ISBN 9788589248136
Nº de págs.: 962
Capa flexível
Formato: 16 x 23 cm

    Manual de Medicamentos Citostáticos é um livro com todos os fundamentos necessários para uso pela Equipe Multiprofissional que atuam em Unidades ou Centros de Assistência de Alta Complexidade em Oncologia (CACON), que apresenta informações sobre medicamentos citostáticos para todos os estudantes e profissionais da área de saúde, com o objetivo de complementar uma abordagem multiprofissional ao paciente oncológico. Livro contendo 184 medicamentos e com os seguintes capítulos: glossário farmacêutico, glossário de oncologia, lista de abreviaturas e siglas, tabela geral de diluição, manipulação de drogas citostáticas, PGRSS com pictogramas e símbolos de identificação de grupos de resíduos, medicamentos com resumo das toxicidades e as monografias dos medicamentos. Neste sentido, o livro aborda as seguintes informações:  nome genérico do produto,  nomes comerciais, sinonímia e outras denominações, forma farmacêutica, categoria terapêutica, farmacocinética, posologia, reações adversas, regimes especiais de posologia, alertas de administração, precauções, interações medicamentosas, condutas na superdose, medidas após a contaminação acidental, protocolo para extravasamento, biossegurança ocupacional, normas internacionais de transporte do produto, PGRSS, estabilidade da solução reconstituída no frasco de vidro, concentração após reconstituição no frasco de vidro,  vias e formas de administração, diluentes, volume final e tempo de infusão, compatibilidade com as soluções e com os equipamentos,  incompatibilidade com as soluções e com os equipamentos, estabilidade em seringa plástica, estabilidade em bolsa plástica de PVC, poliolefina, PEBD e de EVA. Considero este livro uma futura publicação multiprofissional indispensável para todos os profissionais da área de saúde, que necessitam de informações atualizadas e precisas, abordando de maneira clara, simples e objetiva os estudos, principalmente, sobre protocolos para extravasamento, em condutas na superdose e na contaminação acidental, normas do PGRSS, assim como a diluição, compatibilidade e estabilidade de medicamentos citostáticos.

05 março 2014

IMPLEMENTATION OF A CLINICAL PHARMACY AND MEDICINES DISPENSING SERVICE IN A CHEMOTHERAPY DAY TREATMENT UNIT

N Stoner, B Vadher, J Floyd, E Sparkes, C Henriquez.

Oxford University Hospitals NHS Trust, Pharmacy, Oxford, UK

Background Cancer patients at the Oxford University Hospitals NHS Trust receive the majority of their chemotherapy treatments as daycase patients. The clinical pharmacy service provision to patients receiving chemotherapy did not move with the patients from the inpatient to the daycase setting. The lack of clinical pharmacy provision to the day treatment unit (DTU) resulted in medicines wastage and an increase in nursing time to educate patients on their medication.

Purpose The pharmacy service to the DTU was reconfi gured to provide a clinical pharmacy and medicines management service, and to dispense medicines as pre-packs at the patients’ bedside.

Materials and Methods One pharmacist and half of a technician were funded from cost savings to implement the new service. Medication record cards were developed for each supportive regimen as a counselling aid to patients. A patient satisfaction survey was undertaken prior to initiating the new service, and two months after initiation. Drug expenditure and medicine wastage savings were recorded prior to and two months after implementation of the service. A satellite pharmacy was set up to dispense medicines next to the DTU. A trolley was used to dispense pre-packs at the bedside. Data was collected prior to and two months after initiation of the new service to assess patient satisfaction, impact on nursing time, medicines wastage and savings.

Results It was anticipated that approximately £25,000 [€31,000] per month would be saved on medicines wastage. Patients were very satisfi ed with the new service. The service resulted in a reduction in nursing time of 37.5 hours/week. The results of the service impact after two months will be presented.

Conclusions The DTU pharmacy service ensures medicines optimisation, reduces medicines expenditure, and improves the quality of patient care. Patients receiving chemotherapy as inpatients always benefited from a clinical pharmacy service, so it is appropriate to provide this service in the day case setting.

Reference Eur J Hosp Pharm 2013;20(Suppl 1):A1–238

MANAGEMENT OF MYELODISPLASTIC SYNDROMES AND LYMPHOMAS: THE EXAMPLE OF LENALIDOMIDE

M Scaldaferri, E Sciorsci, F Re, C Calvo, M Chiumente, D Barilà, A Chiesa, M Ferroni, S Stecca, F Cattel.

A.O.U. San Giovanni Battista, Pharmacy, Turin, Italy; University of Turin, Faculty of Pharmacy, Turin, Italy; 3University of Turin, School of Hospital Pharmacy, Turin, Italy

Background At our centre, haematologists and department pharmacists constantly monitor outcomes and safety of treatment with lenalidomide.

Purpose To describe clinical outcomes and safety of lenalidomide in our lymphoma and myelodysplastic syndrome patients.

Materials and Methods Onco-AIFA Registry and medical records were checked as of 30/06/2012 for diagnosis, duration of treatment, incidence of adverse drug events (ADRs).

Results Data of 34 patients were reviewed, with the following diagnoses: Diffuse large B-cell lymphoma (DLBCL), 24 patients; 5q-myelodysplastic syndrome (MDS5q-), 11 patients and mantle cell lymphoma (MCL), one patient. Of patients with DLBCL, one discontinued treatment because of serious ADRs, two because of death and 4 for disease progression after an average of 4.4 treatment cycles, corresponding to 7 months (range: 2–18). Of patients with MDS5q-, 8 stopped treatment, two of whom because of disease progression or death and two for toxicity. The median duration of treatment was 11.8 cycles (range 1–29). Seventeen DLBCL patients and 3 MDS5q- patients are still on therapy. 34 non-serious ADRs relating to 14 patients and 5 serious ADRs relating to 4 patients were reported, two of which were cases of development of solid neoplasia. Non-serious ADRs were mostly cases of haematological toxicity, alterations of the skin and of nervous system and infections.

Conclusions Lenalidomide seems to control the disease in patients with MDS5q- for long periods, while the Time to Progression in patients with DLBCL appears shorter. The treatment-related toxicity appears in most cases acceptable. Despite the limited number of data, our analysis highlights the need for close monitoring of the patients both during treatment and on follow-up, as evidenced by the two cases of onset of neoplasia. The progressive collection of data is providing the haematologists and pharmacists the information to design a model for optimised appropriate treatment with lenalidomide.

Reference Eur J Hosp Pharm 2013;20(Suppl 1):A1–238